Merck & Co. (MRK) : Private Wealth Partners scooped up 1,741 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 213,689 shares of Merck & Co. which is valued at $11,718,705.Merck & Co. makes up approximately 2.80% of Private Wealth Partners’s portfolio.
Merck & Co. opened for trading at $54.85 and hit $55.36 on the upside on Monday, eventually ending the session at $55.3, with a gain of 0.84% or 0.46 points. The heightened volatility saw the trading volume jump to 96,78,915 shares. Company has a market cap of $153,472 M.
Other Hedge Funds, Including , Wilbanks Smith Thomas Asset Management boosted its stake in MRK in the latest quarter, The investment management firm added 2,168 additional shares and now holds a total of 38,235 shares of Merck & Co. which is valued at $2,096,807. Merck & Co. makes up approx 0.25% of Wilbanks Smith Thomas Asset Management’s portfolio.Gw&k Investment Management boosted its stake in MRK in the latest quarter, The investment management firm added 17,920 additional shares and now holds a total of 325,555 shares of Merck & Co. which is valued at $18,471,991. Merck & Co. makes up approx 0.41% of Gw&k Investment Management’s portfolio.Bennicas Associates reduced its stake in MRK by selling 2,600 shares or 4.33% in the most recent quarter. The Hedge Fund company now holds 57,408 shares of MRK which is valued at $3,257,330. Merck & Co. makes up approx 3.03% of Bennicas Associates’s portfolio.1st Global Advisors reduced its stake in MRK by selling 1,045 shares or 5.48% in the most recent quarter. The Hedge Fund company now holds 18,013 shares of MRK which is valued at $1,011,250. Merck & Co. makes up approx 0.14% of 1st Global Advisors’s portfolio.Atalanta Sosnoff Capital reduced its stake in MRK by selling 276,059 shares or 36.96% in the most recent quarter. The Hedge Fund company now holds 470,759 shares of MRK which is valued at $26,428,410. Merck & Co. makes up approx 0.82% of Atalanta Sosnoff Capital’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.